Resource Logo
NLM AIDSLINE

Todoxin--HIV inhibitory and immunostimulating efficacy.




 

Int Conf AIDS. 1994 Aug 7-12;10(2):115 (abstract no. PA0340). Unique

OBJECTIVE: Todoxin is a novel antiviral and immunostimulating preparation based upon an ion carrier molecule with specific binding affinities and a carrier specific substrate formulation. Todoxin's formulation is unique in three aspects: 1. It comprises a very broad spectrum of physiologically active, cis-oriented and water soluable carbohydrates, carboxylic acids, vitamins, fat soluable vitamins, coenzymes and enzymes such as Amylases, Phosphatases and Catalases. 2. It contains both agonic and antagonic agents such as Ca and Fe in physiologically relevant concentrations. 3. It contains a spectrum of minerals in permanent solution. Induction of desired cell physiologic effects in vitro such as increase in cellular exchange diffusion, uptake of substrates, metabolites, oxydative phosphorylation, mitogen response of RET cells, have previously been described by author. We report here: (a) Todoxin's efficacy to increase Natural Killer (NK) cell activity in vitro. (b) Todoxin's efficacy to inhibit HIV transfection in vitro. METHODS: (a) Peripheral blood lymphocytes were treated with Todoxin for 17 h and tested for killing of B cell lymphoma cell line DAUDI in a 3 h Cr51-release assay. Treatments were done in medium or IL-2 (10 U/ml). The highest Todoxin concentration was a final dilution of 1:10 with 4 consecutive dilution steps 1:10. (b) HIV infected CEM-IW cells were incubated 7 days with fraction of Todoxin. Concurrent studies were performed on different sample concentrations. The lowest sample concentration was 6.0 x 10-1 ug/ml with increasing steps of Log10. RESULTS: (a) Todoxin increases NK killing to the same levels as IL-2 does. (b) Todoxin prevents HIV infection in vitro 100% as per uninfected untreated control culture. CONCLUSION: The described results may in part explain the potent therapial effects of Todoxin seen in viral disease including slow virus infection, retrovirus and virus associated carcinogenesis. TABULAR DATA, SEE ABSTRACT VOLUME.

Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/CHEMISTRY/ *PHARMACOLOGY Antiviral Agents/ADMINISTRATION & DOSAGE/CHEMISTRY/*PHARMACOLOGY Cytotoxicity, Immunologic/DRUG EFFECTS Human HIV/*DRUG EFFECTS/GENETICS HIV Infections/PREVENTION & CONTROL In Vitro Interleukin-2/PHARMACOLOGY Killer Cells, Natural/DRUG EFFECTS/IMMUNOLOGY Transfection/DRUG EFFECTS Tumor Cells, Cultured/IMMUNOLOGY ABSTRACT



 




Information in this article was accurate in December 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.